This issue of Rheumatic Disease Clinics, guest edited by Drs. Andrew Bomback and Meghan Sise, will cover several key aspects of Renal Involvement in Rheumatic Diseases. The Consulting Editor for the series is Dr. Michael Weisman. The topics discussed in the issue will include: ANCA, Lupus GN, proliferative and non-proliferative, Renal manifestations of RA, Secondary amyloidosis, Nephrotoxicity of select rheumatology drugs, Acute and chronic TI nephritis, rheumatology etiologies, TMAs with rheum etiologies, Anti-GBM, Autoimmune manifestations of viral infections, and Renal manifestations of IBD, among others.

Presenting the views of world experts on the causes and treatment of kidney diseases that complicate various rheumatologic diseases, this book includes pathogenesis, clinical features and treatment of diseases providing a readily accessible source of clinical advice for day-to-day practice.

This Open Access book presents practical approaches to managing patients affected by various rheumatological diseases, allowing readers to gain a better understanding of the various clinical expressions and problems experienced by these patients. Discussing rheumatology from an organ systems perspective, it highlights the importance ofdetailed musculoskeletal examinations when treating patients affected by rheumatological diseases. The book first explores the latest diagnostic approaches and offers key tips for accurate musculoskeletal examinations before addressing the various treatment modalities, with a particular focus on the most common joints involved in rheumatoid arthritis: the wrists and the metacarpophalangeal joints (2nd and 3rd). Featuring easy-to-understand flow diagrams and explaining the common medical problems associated with rheumatic disease, such as shortness of breath and anemia, it is not only a valuable resource to rheumatologists, but will also appeal to medical students, junior residents, and primary healthcare physicians.

This volume brings together an international group of clinicians and clinical scientists to contribute to a state-of the-art review of the underlying pathogenic mechanisms, methods of clinical assessment, classification and diagnosis of renal disease, combined with a detailed overview of treatment strategies. An essential reference source for all those involved with the care of patients with renal involvement in systemic autoimmune disease, and for those contributing to research into the underlying pathogenic mechanisms in these disorders.

This issue of Rheumatic Disease Clinics, guest edited by Dr. Candace Feldman, is Part II of a two-part issue covering Health Disparities in Rheumatic Diseases. This issue is one of four selected each year by series Consulting Editor, Dr. Michael Weisman. Topics discussed in this issue include, but are not limited to: Disparities in Lupus Care and Outcomes among U.S. Medicaid Beneficiaries, Understanding Risk Factors for Poor Outcomes in a Multiethnic Longitudinal Cohort, Impact of Psychosocial Factors on RA and Lupus Health Disparities, Racial/ethnic and geographic disparities in knee and hip osteoarthritis, Racial/ethnic Disparities in Osteoarthritis Management, Challenges and Strategies to Achieve Equitable Rheumatologic Care Across the World, Strategies to Reduce Disparities, Understanding and Addressing the Provider Biases and the Lack of Diversity in Lupus Clinical Trials, Community-engaged Research: Lupus Conversations, Leveraging Telemedicine as an Approach to Address Rheumatic Disease Health Disparities, and Understanding the Role and Challenges of Patient Preferences in Disparities in Rheumatic Disease Care.

A strong clinical emphasis is present throughout this volume from the first section of commonly presenting problems through to the section addressing problems shared with a range of other clinical sub-specialties.

"Rheumatic Disease" is the second monograph in a new series on management and treatment in major clinical subspecialties and patient groups. Further volumes will be published over the next few years. Each book is complete in its own right. The whole series, however, has been prepared to fill a gap, perceived by the publisher, myself and the volume authors, between standard text books of medicine and therapeutics and research reviews, sympo sia' and original articles in specialist fields. Each volume aims to provide a concise, up to date account of treatment in its subject area with particular reference to drug therapy. Wherever pos sible, authorship has been undertaken by practising clinicians who themselves have training and experience in clinical pharma cology. The volumes are intended to be guides to treatment, to assist in the choice of drug and other treatment and to provide easy references to drug interactions and adverse reactions. The aims of the series should be upheld by this volume on "Rheumatic Disease". The book has been prepared in Glasgow and Newcastle. The authors, Drs. Hilary Capell, Terry Daymond and Carson Dick, are not only respected clinicians and rheumato logists but have wide clinical and research experience in the clinical pharmacology of antirheumatic drugs and therapeutic management of connective tissue disease and other areas of rheumatology. This volume combines practical pragmatic man agement with new concepts in drug treatment.

Seer, forecaster, prophet, geomancer, or tout - all predict future events as physicians must. The medical activity is prognosis from the Greek pro (forward) and gnosis (special knowledgeL thus foreknowledge, and the practitioner is the prognosticator, a sobriquet which falls unhappily upon the ear. Like it or not, there is nothing more critical in the management of chronic rheumatic conditions than a reasonably clear picture of what time and disease will bring. The knowledge is so much a part of ordinary medical thinking that we rarely grace it with the label prognosis. But, like so much of "ordinary medical thinking" (an oxymoron, perhaps), quantitative data are very thin and the chestnuts of personal observation and authority figure assertion loom large. Unlike several books I have seen or written, this one on prognosis needs no justification. The entirety of a person's life contributes to and confounds what the future holds. The ingredients include education levet income, support structures such as family, housing, occupation, availability of medical services, diagnosis, treatment, rate of disease progression, age, gender, race, marital status, and others too numerous to mention or too arcane to be recognized. One would think the task of estimating prognosis impossible. And yet there is light on the horizon -we do know a few things such as the effect of high rheumatoid factor titers on the prognosis of RA or the likely outcome of certain kidney lesions in SLE.